Renaissance Pharma Secures FDA Breakthrough Therapy Designation for Daretabart in Paediatric Neuroblastoma

17 November 2026 | Tuesday | News

The FDA has granted Breakthrough Therapy Designation to investigational anti-GD2 antibody daretabart in combination with induction chemotherapy for newly diagnosed high-risk neuroblastoma in children. The designation is supported by Phase 2 data showing 73.7% event-free survival and 86% overall survival at three years, with further clinical development planned
Image Source: Public Domain

Image Source: Public Domain

Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patients

First Breakthrough Therapy Designation (BTD) for daretabart, an investigational anti-GD2 humanised monoclonal antibody

Daretabart is an investigational asset and has not been approved for use by any regulatory authority

Renaissance Pharma Limited (Renaissance Pharma), an Essential Pharma company focused on development stage assets, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for use of daretabart (hu14.18K322A) in combination with induction chemotherapy, for the first-line treatment of paediatric patients with newly diagnosed high-risk neuroblastoma (HRNB).

This designation was supported by Phase II data published in the Journal of Clinical Oncology in December 20211. The study was an open label, single arm Phase II trial at one centre in 64 children with newly diagnosed HRNB. Three-year event-free survival (EFS) was 73.7% (95% CI 60.0 to 83.4) and three-year overall survival (OS) was 86.0% (95% CI 73.8 to 92.8). Grade 3 or 4 toxicities attributed to the antibody infusion during induction included pain (10% of 379 cycles), hypoxia (6%), infusion related reactions (4%), hypotension (3%) and cough (1%).

The FDA's BTD program is intended to expedite the development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Simon Ball, President of Renaissance Pharma said, “We look forward to executing our clinical development strategy, including our ongoing SHINE study in relapsed and refractory disease, together with our future planned induction study, to bring this antibody to the neuroblastoma community.”

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close